Eisai Parades Pipeline Before Investors During First US R&D Day
Executive Summary
Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
You may also be interested in...
Eisai Cancer Subsidiary H3 Pushes Toward The Clinic
H3 Biomedicine is using publicly available cancer genomics data to discover compounds that could treat small subsets of patients.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.